European Journal of Clinical Pharmacology

, Volume 64, Issue 1, pp 1–8 | Cite as

Endocannabinoids in platelets of chronic migraine patients and medication-overuse headache patients: relation with serotonin levels

  • Cristiana Rossi
  • Luigi Alberto Pini
  • Maria Letizia Cupini
  • Paolo Calabresi
  • Paola Sarchielli
Clinical Trial

Abstract

Background

Chronic migraine (CM) and medication-overuse headaches (MOH) are well-recognized disabling conditions affecting a significant portion of the headache population attending centers specialized in treating headaches. A dysfunctioning of the serotonergic system has been demonstrated in MOH and CM patients. Here we report on our assessment of the dysfunctioning of the endocannabinoid system as a potential underlying factor in pathogenic mechanisms involved in CM and MOH.

Method

To test the hypothesis of an impairment in the endocannabinoid system in patients with MOH and CM and to assess its relationship with any disruption of the serotonergic system, we determined the levels of the two main endogenous cannabinoids, anandamide (AEA) and 2-acylglycerol (2-AG), in platelets of 20 CM patients, 20 MOH patients and 20 control subjects and also measured the platelet serotonin levels in the same patients.

Results

We found that 2-AG and AEA levels were significantly lower in MOH patients and CM patients than in the control subjects, without significant differences between the two patient groups. Serotonin levels were also strongly reduced in the two patient groups and were correlated with 2-AG levels, with higher values for MOH patients.

Conclusion

These data support the potential involvement of a dysfunctioning of the endocannabinoid and serotonergic systems in the pathology of CM and MOH. These systems appear to be mutually related and able to contribute to the chronification of both CM and MOH.

Keywords

Chronic headache Endocannabinoids Medication-overuse headache Serotonin 

References

  1. 1.
    Pascual J, Colas R, Castillo J (2001) Epidemiology of chronic daily headache. Curr Pain Headache Rep 5:529–536Google Scholar
  2. 2.
    Diener HC, Limmroth V (2004) Medication-overuse headache: a worldwide problem. Lancet Neurol 3:475–483PubMedCrossRefGoogle Scholar
  3. 3.
    Boes CJ, Black DF, Dodick DW (2006) Pathophysiology and management of transformed migraine and medication overuse headache. Semin Neurol 26:232–241PubMedCrossRefGoogle Scholar
  4. 4.
    Srikiatkhachorn A (2001) Pathophysiology of chronic daily headache. Curr Pain Headache Rep 5:537–544PubMedCrossRefGoogle Scholar
  5. 5.
    Welch KM (2003) Concepts of migraine headache pathogenesis: insights into mechanisms of chronicity and new drug targets. Neurol Sci 24(Suppl 2):S149–S153PubMedGoogle Scholar
  6. 6.
    Cupini LM, Calabresi P (2005) Medication-overuse headache: pathophysiological insights. J Headache Pain 6:199–202PubMedCrossRefGoogle Scholar
  7. 7.
    Calabresi P, Cupini LM (2005) Medication-overuse headache: similarities with drug addiction. Trends Pharmacol Sci 26:62–68PubMedCrossRefGoogle Scholar
  8. 8.
    Fumal A, Laureys S, Di Clemente L, Boly M, Bohotin V, Vandenheede M, Coppola G, Salmon E, Kupers R, Schoenen J (2006) Orbitofrontal cortex involvement in chronic analgesic-overuse headache evolving from episodic migraine. Brain 129:543–550PubMedCrossRefGoogle Scholar
  9. 9.
    D’Andrea G, Cananzi AR, Perini F, Hasselmark L (1995) Platelet models and their possibile usefulness in the study of migraine pathogenesis. Cephalagia 15:265–271CrossRefGoogle Scholar
  10. 10.
    Gallai V, Floridi A, Mazzotta G, Codini M, Tognoloni M, Ambrosini P et al (1996) L-arginine/nitric oxide patway activation in platelets of migraine with and without aura patients. Acta Neurol Scand 94:151–160PubMedGoogle Scholar
  11. 11.
    Hering R, Glover V, Pattichis K, Catarci T, Steiner TJ (1993) 5HT in migraine patients with medication-induced headache. Cephalalgia 13:410–412PubMedCrossRefGoogle Scholar
  12. 12.
    Srikiatkhachorn A, Govitrapong P, Limthavon C (1994) Up-regulation of 5-HT2 serotonin receptor: a possible mechanism of transformed migraine. Headache 34:8–11PubMedCrossRefGoogle Scholar
  13. 13.
    Srikiatkhachorn A, Maneesri S, Govitrapong P, Kasantikul V (1998) Derangement of serotonin system in migrainous patients with analgesic abuse headache: clues from platelets. Headache 38:43–49PubMedCrossRefGoogle Scholar
  14. 14.
    Sarchielli P, Alberti A, Russo S, Codini M, Panico R, Floridi A, Gallai V (1999) Nitric oxide pathway, Ca2+, and serotonin content in platelets from patients suffering from chronic daily headache. Cephalalgia 19:810–816PubMedCrossRefGoogle Scholar
  15. 15.
    Calignano A, La Rana G, Giuffrida A, Piomelli D (1998) Control of pain initiation by endogenous cannabinoids. Nature 394:277–281PubMedCrossRefGoogle Scholar
  16. 16.
    Walker JM, Hohmann AG (2005) Cannabinoid mechanisms of pain suppression. Handb Exp Pharmacol 168:509–554PubMedCrossRefGoogle Scholar
  17. 17.
    Akerman S, Kaube H, Goadsby PJ (2004) Anandamide is able to inhibit trigeminal neurons using an in vivo model of trigeminovascular-mediated nociception. J Pharm Exp Ther 309:56–63CrossRefGoogle Scholar
  18. 18.
    Quartilho A, Mata HP, Ibrahim MM, Vanderah TW, Porreca F, Makriyannis A, Malan TP Jr (2003) Inhibition of inflammatory hyperalgesia by activation of peripheral CB2 cannabinoid receptors. Anesthesiology 99:955–960PubMedCrossRefGoogle Scholar
  19. 19.
    Kimura T, Ohta T, Watanabe K, Yoshimura H, Yamamoto I (1998) Anandamide, an endogenous cannabinoid receptor ligand, also interacts with 5-hydroxytryptamine (5-HT) receptor. Biol Pharmacol Bull 21:224–226Google Scholar
  20. 20.
    Cheer JF, Cadogan AK, Marsden CA, Fone KC, Kendall DA (1999) Modification of 5-HT2 receptor mediated behaviour in the rat by oleamide and the role of cannabinoid receptors. Neuropharmacology 38:533–541PubMedCrossRefGoogle Scholar
  21. 21.
    Maione S, Bisogno T, de Novellis V, Palazzo E, Cristino L, Valenti M, Petrosino S, Guglielmotti V, Rossi F, Di Marzo V (2006) Elevation of endocannabinoid levels in the ventrolateral periaqueductal grey through inhibition of fatty acid amide hydrolase affects descending nociceptive pathways via both cannabinoid receptor type 1 and transient receptor potential vanilloid type-1 receptors. J Pharmacol Exp Ther 316:969–982PubMedCrossRefGoogle Scholar
  22. 22.
    Parolaro D, Vigano D, Rubino T (2005) Endocannabinoids and drug dependence. Curr Drug Targets CNS Neurol Disord 4:643–655PubMedCrossRefGoogle Scholar
  23. 23.
    Maccarrone M, Bari M, Battista N, Finazzi-Agro A (2002) Endocannabinoid degradation, endotoxic shock and inflammation. Curr Drug Targets Inflamm Allergy 1:53–63PubMedCrossRefGoogle Scholar
  24. 24.
    Macarrone M, Bari M, Menichelli A, Giuliani E, Del Principe D, Finazzi-Agro A (2001) Human platelets bind and degrade 2-arachidonoylglycerol, which activates these cells through a cannabinoid receptor. Eur J Biochem 268:819–825, FebCrossRefGoogle Scholar
  25. 25.
    Maccarrone M, Bari M, Principe DD, Finazzi-Agro A (2003) Activation of human platelets by 2-arachidonoylglycerol is enhanced by serotonin. Thromb Haemost 89:340–347PubMedGoogle Scholar
  26. 26.
    Braud S, Bon C, Touqui L, Mounier C (2000) Activation of rabbit blood platelets by anandamide through its cleavage into arachidonic acid. FEBS Lett 471:12–16PubMedCrossRefGoogle Scholar
  27. 27.
    Berdyshev EV, Schmid PC, Krebsbach RJ, Schmid HH (2001) Activation of PAF receptors results in enhanced synthesis of 2-arachidonoylglycerol (2-AG) in immune cells. FASEB J 15:2171–2178PubMedCrossRefGoogle Scholar
  28. 28.
    Cupini LM, Bari M, Battista N, Argiro G, Finazzi-Agro A, Calabresi P, Maccarrone M (2006) Biochemical changes in endocannabinoid system are expressed in platelets of female but not male migraineurs. Cephalalgia 26:277–281PubMedCrossRefGoogle Scholar
  29. 29.
    Headache Classification Subcommittee of the International Headache Society (2004) The international classification of headache disorders: 2nd edition. Cephalalgia 24(Suppl 1):9–160Google Scholar
  30. 30.
    Silberstein SD, Olesen J, Bousser MG, Diener HC, Dodick D, First M, Goadsby PJ, Göbel H, Lainez MJA, Lance JW, Lipton RB, Nappi G, Sakai F, Schoenen J, Steiner TJ, on behalf of the International Headache Society (2005) The international classification of Headache Disorders, 2nd Edition (ICHD-II)-revision of criteria for 8.2 Medication-overuse headache. Cephalalgia 25:460–465PubMedCrossRefGoogle Scholar
  31. 31.
    Headache Classification Committee, Olesen J, Bousser MG, Diener HC, Dodick D, First M, Goadsby PJ, Gobel H, Lainez MJ, Lance JW, Lipton RB, Nappi G, Sakai F, Schoenen J, Silberstein SD, Steiner TJ (2006) New appendix criteria open for a broader concept of chronic migraine. Cephalalgia 26:742–746PubMedCrossRefGoogle Scholar
  32. 32.
    Lingjaerde O (1990) Blood platelets as a model system for studying serotonergic dysfunction and effects of antidepressants. Pharmacol Toxicol 66(Suppl 3):61–68PubMedCrossRefGoogle Scholar
  33. 33.
    Uebelhack R, Franke L, Herold N, Plotkin M, Amthauer H, Felix R (2006) Brain and platelet serotonin transporter in humans-correlation between [123I]-ADAM SPECT and serotonergic measurements in platelets. Neurosci Lett 406:153–158, Epub 2006 Aug 24PubMedCrossRefGoogle Scholar
  34. 34.
    Vogeser M, Hauer D, Christina Azad S, Huber E, Storr M, Schelling G (2006) Release of anandamide from blood cells. Clin Chem Lab Med 44:488–491PubMedCrossRefGoogle Scholar
  35. 35.
    Sarchielli P, Pini LA, Coppola F, Rossi C, Baldi A, Mancini ML, Calabresi P (2007) Endocannabinoids in chronic migraine: CSF findings suggest a system failure. Neuropsychopharmacology 32:1384–1390PubMedCrossRefGoogle Scholar
  36. 36.
    Akerman S, Holland PR, Goadsby PJ (2007) Cannabinoid (CB1) receptor activation inhibits trigeminovascular neurons. J Pharmacol Exp Ther 320:64–71PubMedCrossRefGoogle Scholar
  37. 37.
    Maldonado R, Valverde O, Berrendero F (2006) Involvement of the endocannabinoid system in drug addiction. Trends Neurosci 29:225–232CrossRefGoogle Scholar
  38. 38.
    Fattore L, Spano MS, Deiana S, Melis V, Cossu G, Fadda P, Fratta W (2007) An endocannabinoid mechanism in relapse to drug seeking: a review of animal studies and clinical perspectives. Brain Res Rev 53:1–16PubMedCrossRefGoogle Scholar
  39. 39.
    González S, Cascio MG, Fernández-Ruiz J, Fezza F, Di Marzo V, Ramos JA (2002) Changes in endocannabinoid contents in the brain of rats chronically exposed to nicotine, ethanol or cocaine. Brain Res 954:73–81PubMedCrossRefGoogle Scholar
  40. 40.
    Ferrer B, Bermúdez-Silva FJ, Bilbao A, Alvarez-Jaimes L, Sanchez-Vera I, Giuffrida A, Serrano A, Baixeras E, Khaturia S, Navarro M, Parsons LH, Piomelli D, Rodriguez de Fonseca F (2007) Regulation of brain anandamide by acute administration of ethanol. Biochem J 404:97–104PubMedCrossRefGoogle Scholar
  41. 41.
    Beardsley PM, Thomas BF (2005) Current evidence supporting a role of cannabinoid CB1 receptor (CB1R) antagonists as potential pharmacotherapies for drug abuse disorders. Behav Pharmacol 16:275–296PubMedCrossRefGoogle Scholar
  42. 42.
    Tucci SA, Halford JC, Harrold JA, Kirkham TC (2006) Therapeutic potential of targeting the endocannabinoids: implications for the treatment of obesity, metabolic syndrome, drug abuse and smoking cessation. Curr Med Chem 13:2669–2680PubMedCrossRefGoogle Scholar
  43. 43.
    Sipe JC, Chiang K, Gerber AL, Beutler E, Cravatt BF (2002) A missense mutation in human fatty acid amide hydrolase associated with problem drug use. Proc Natl Acad Sci USA 99:8394–8399PubMedCrossRefGoogle Scholar
  44. 44.
    Parrish JC, Nichols DE (2006) Serotonin 5-HT(2A) receptor activation induces 2-arachidonoylglycerol release through a phospholipase c-dependent mechanism. J Neurochem 99:1164–1175PubMedCrossRefGoogle Scholar
  45. 45.
    Gobbi G, Bambico FR, Mangieri R, Bortolato M, Campolongo P, Solinas M, Cassano T, Morgese MG, Debonnel G, Duranti A, Tontini A, Tarzia G, Mor M, Trezza V, Goldberg SR, Cuomo V, Piomelli D (2005) Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc Natl Acad Sci USA 102(51):18620–18625, Erratum in: Proc Natl Acad Sci USA 103:2465, 2006PubMedCrossRefGoogle Scholar
  46. 46.
    Vandevoorde S, Lambert DM (2005) Focus on the three key enzymes hydrolysing endocannabinoids as new drug targets. Curr Pharm Des 11:2647–2668PubMedCrossRefGoogle Scholar
  47. 47.
    Bari M, Battista N, Fezza F, Gasperi V, Maccarrone M (2006) New insights into endocannabinoid degradation and its therapeutic potential. Mini Rev Med Chem 6:257–268PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Cristiana Rossi
    • 1
  • Luigi Alberto Pini
    • 2
  • Maria Letizia Cupini
    • 3
  • Paolo Calabresi
    • 1
    • 4
  • Paola Sarchielli
    • 1
    • 5
  1. 1.Neurologic Clinic, Department of Medical and Surgical Specialties and Public HealthUniversity of PerugiaPerugiaItaly
  2. 2.Institute of Clinical PharmacologyUniversity of ModenaModenaItaly
  3. 3.U.O.C. Neurologia, Dipartimento Cranio SpinaleOspedale S. EugenioRomeItaly
  4. 4.IRCCS Fondazione S. LuciaRomeItaly
  5. 5.Neurologic ClinicOspedale Santa Maria della MisericordiaSan Sisto-PerugiaItaly

Personalised recommendations